KYIV. Feb 16 (Interfax-Ukraine) – Biofarma pharmaceutical company (Kyiv region) as part of the implementation of the project on reconstruction of the Sumy blood donor center plans to restore the regular donor institution to receive high-quality blood for production of blood products.
“Today we’re forming the regular donor institution… Mainly we need to receive high-quality blood components for hospitals and plasma for the fractionator plant. It’s not a secret that there is a high level of virus diseases in Ukraine, as HIV, hepatitis, including hepatitis C, tuberculosis,” Board Chairman Kostiantyn Yefymenko said in an interview with Interfax-Ukraine.
He also said that Biofarma started construction of a blood plasma fractionator with a projected capacity of 400 tonnes in 2015. In April 2016, the company plans to sign contracts to supply equipment for the plant.
“We’ve invested in the Sumy regional blood center to supply enough high-quality blood to the fractionator plant. It is being reconstructed by Biofarma in partnership with Sumy region. We’ve fully modernized the regional blood center. We actually removed everything old one and build a new center which today collects 3 tonnes of plasma a month and it is able to boost it to 5 tonnes,” he said.
Yefymenko said that the company plans to resume donor culture which was lost at many blood centers.
“Our task is to attract as many as possible regular donors who we’re confident of,” he said.
Yefymenko said that the Sumy blood donor center is one of few examples of the successful public private partnership. The Biofarma’s investment in the project reached around $3 million.
Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
Niobera Investments Limited (Cyprus) holds 100% in Biofarma. According to the National Commission for Securities and the Stock Market of Ukraine, Biofarma Board Chairman Kostiantyn Yefymenko is the ultimate beneficiary of a large shareholder in Niobera Investments Limited. Shares do not belong to members of the executive body.
In 2014, Biofarma built a pharmaceutical plant in Bila Tserkva (Kyiv region). Investment totaled $42 million.
In 2014, Biofarma cut its net profit by 9.91% from a year ago, to UAH 25.801 million.